Therapies targeting receptor tyrosine kinases (RTK) can induce immunogenic modulation either by improving the cytotoxic function of the adaptive immune system, or by blocking expression of immunosuppressive molecules such as PD-L1, to enhance T cell mediated elimination of cancer cells. This evidence concerns the gene CD274 and cancer.